Forward-looking Statements

This presentation includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of the COVID-19 global pandemic; the war in Ukraine and escalating geopolitical tensions as a result of Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of increasing inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; the impacts of the completed spin-off of ESAB Corporation into an independent publicly traded company (the “Separation”); the potential to incur significant liability if the Separation is determined to be a taxable transaction; the ability to realize the anticipated benefits of the Separation, the financial and operating performance of the Company following the Separation; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This presentation speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Non-GAAP Financial Information

Enovis has provided in this presentation financial information that has not been prepared in accordance with accounting principles generally accepted in the United States of America (“non-GAAP”). These non-GAAP financial measures may include one or more of the following: adjusted net income from continuing operations, adjusted net income per diluted share from continuing operations, adjusted EBITDA (earnings before interest, taxes, depreciation and amortization), adjusted EBITDA margin and organic sales growth. Adjusted net income from continuing operations and adjusted net income per diluted share from continuing operations exclude restructuring and other charges, European Union Medical Device Regulation (“MDR”) and other costs, amortization of acquired intangibles, inventory step-up costs, strategic transaction costs, debt extinguishment charges, insurance settlement gain, gains and losses on the Company’s investments, stock compensation costs and other income. Adjusted net income adjusts interest expense for periods prior to 2023 to reflect pro forma interest from the Company’s term loan facility under the Company’s current capital structure after giving effect to the completing of the refinancing transactions in connection with the Separation, and it includes the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments. Enovis also presents adjusted net income margin from continuing operations, which is subject to the same adjustments as adjusted net income from continuing operations. Adjusted EBITDA represents operating income from continuing operations excluding restructuring and other charges, MDR and other costs, strategic transaction costs, stock-based compensation costs, depreciation and amortization, amortization of acquired intangibles, insurance settlement gain, and inventory step up costs. Enovis presents adjusted EBITDA margin, which is subject to the same adjustments as adjusted EBITDA. Organic sales growth excludes the impact of acquisitions and foreign exchange rate fluctuations. Sales per day growth includes the same adjustments as Organic sales growth and adjusts for the number of selling days in the period. These non-GAAP financial measures assist Enovis management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans that are fundamentally different from the ongoing productivity improvements of the Company. Enovis management also believes that presenting these measures allows investors to view its performance using the same measures that the Company uses in evaluating its financial and business performance and trends. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of non-GAAP financial measures presented above to GAAP results has been provided in the financial tables included in this presentation. Enovis does not provide reconciliations of adjusted EBITDA or adjusted earnings per share on a forward-looking basis to the closest GAAP financial measures, as such information is not available without unreasonable efforts on a forward-looking basis due to uncertainties regarding, and the potential variability of, reconciling items excluded from these measures. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period.
Enovis: An Innovation and Growth driven MedTech company

Financial Profile – 2023 Guidance

<table>
<thead>
<tr>
<th>Sales</th>
<th>aEBITDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>$1.7B</td>
<td>$262-270mm</td>
</tr>
</tbody>
</table>

Sales Mix by Geography & Segment

- United States: 68%
- Europe: 27%
- ROW: 5%

Two Attractive Business Segments

Fast growing reconstructive (Recon) platform
- DD growth engine in US, leading in Shoulder and rapid adoption in Knee & Hip
- Globalized footprint and offering through acquisition of Mathys
- Expanded into attractive Foot & Ankle market in 2021

Global leader in prevention & recovery (P&R)
- Global leader in rigid bracing and soft goods
- Reshaping care path with MotionMD® and MotioniQ™ digital solutions
- Technology leader in recovery sciences with broad offering in advanced rehabilitation modalities

Enovis has sustainable capabilities to outgrow its markets
Addressing a Large and Attractive Market

Enovis competes in half of the $53B Orthopedics market and “touches” nearly all

<table>
<thead>
<tr>
<th>Market</th>
<th>Our Recon served markets</th>
<th>$48B</th>
<th>$5B</th>
<th>Est. Market Growth Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Knee</td>
<td>9</td>
<td></td>
<td></td>
<td>3-4%</td>
</tr>
<tr>
<td>Hip</td>
<td>8</td>
<td></td>
<td></td>
<td>3-4%</td>
</tr>
<tr>
<td>Extremities</td>
<td>3</td>
<td></td>
<td></td>
<td>7-8%</td>
</tr>
<tr>
<td>Trauma</td>
<td>7</td>
<td></td>
<td></td>
<td>3-4%</td>
</tr>
<tr>
<td>Sports Medicine</td>
<td>6</td>
<td></td>
<td></td>
<td>6-7%</td>
</tr>
<tr>
<td>Spine</td>
<td>10</td>
<td></td>
<td></td>
<td>3-4%</td>
</tr>
<tr>
<td>Biologics</td>
<td>5</td>
<td></td>
<td></td>
<td>2-3%</td>
</tr>
</tbody>
</table>

Surgical Implants and Instrumentation  Prevention & Rehabilitation (P&R)

Market Growth Trends Provide Runway

Aging but active population, rising obesity

Transitioning to outpatient care

Innovation improving the quality of care

Well-positioned in the market with strong long-term growth drivers

Established Brands and Accelerating Innovation

Prevention & Recovery Segment

- Footcare
- Recovery Sciences
- Bracing

~$1.1B TTM¹

#1 Globally in Bracing
#1 Globally in Rehab
#2 In Bone Stimulation

Reconstructive Segment

- Foot & Ankle
- Other
- Hip
- Knee

~$0.6B TTM¹

DD
Organic Growth

#3 In US Shoulder

DonJoy®
Aircast®
Chattanooga®
LiteCure®

AltiVate®
EMPOWR Dual Mobility™
EMPOWR® 3D
DynaNail™

Market leading position in P&R and Fast-Growing Recon products

1: Trailing 12 months: 6/30/23 ENOV as reported YTD revenues plus 6 months ended 12/31/2022

© 2023 Enovis Corporation
Uniquely Positioned Across Full Ortho Care Continuum

<table>
<thead>
<tr>
<th>PREVENTION</th>
<th>REPAIR</th>
<th>RECOVERY</th>
<th>PERFORMANCE</th>
<th>PREVENTION</th>
<th>SURGICAL</th>
<th>RECOVERY</th>
<th>REHAB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Athletic braces</td>
<td>• Off-loading braces</td>
<td>• Shoulders</td>
<td>• Post-op braces</td>
<td>• Electrotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Muscle stimulation</td>
<td>• Back braces</td>
<td>• Knees</td>
<td>• Walker boots</td>
<td>• Laser therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Cold therapy</td>
<td>• Hips</td>
<td>• Cold therapy</td>
<td>• Heat/cold therapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Foot/Ankle</td>
<td></td>
<td>• Traction devices</td>
</tr>
</tbody>
</table>

**STRATEGIC ADVANTAGES**

- Brand leverage with hospitals, surgeons, clinicians, patients
- Digital workflow solutions for clinics
- Connected medicine solutions for patient journey
- Full “episode of care” partner to ambulatory surgery centers (ASC)

Broad and deep market access and technology for strategic advantage
Expanding Margins with Clear Strategy & Business System

aEBITDA Margin (%)

>50bps per year

Margin Drivers

- Mix benefits generated by growth in Recon
- Scale and synergy from recent acquisitions
- Operating leverage from growth, productivity, and disciplined price/cost management

Continuous margin improvement leveraging growth and EGX business system
Robust M&A Opportunities to Accelerate Growth

**Expand**
Redefine boundaries

- Expand along Continuum of Care
- Enter Logical Clinic-Based Adjacencies
- Expand Geographically
- Apply Technology in Other Markets
- Add Digital Solutions
- Build around Healthcare Provider
- Enter High-Growth Recon Sub-Segments
- Expand Channels

**Extend**
Build out from core

- Fill Product Line Gaps
- Add High-Growth / High-Margin P&R
- Enter High-Growth Recon Sub-Segments

**Excel**
Win in the core

**Acquisition Criteria**

- Fuels growth
- Improves gross margin
- Accelerates strategy
- Expands market reach
- Creates scale
Recent Recon Acquisitions Enhancing Growth Profile

Recon Globalization

<table>
<thead>
<tr>
<th></th>
<th>Pre-Acquisition</th>
<th>2023e¹ (Yr. 2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growth</td>
<td>MSD</td>
<td>DD</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>~55%</td>
<td>~60%</td>
</tr>
<tr>
<td>aEBITDA Margin</td>
<td>HSD</td>
<td>High Teens</td>
</tr>
</tbody>
</table>

- Globalized surgical business in mid 2021
- AltiVate® and EMPOWR® synergy momentum building
- Scale and productivity will drive EBITDA to mid-20s+

Foot & Ankle Platform

Established a strong portfolio across Foot & Ankle

- 5 acquisitions with a global run rate of ~$100mm sales/yr exiting ’23
- 17% organic YTD sales growth, EBITDA margins from ~0% to DD
- Great momentum for strong DD growth & margin scaling to mid-20s

Strong balance sheet, low net leverage with ~$1B in M&A capacity

1: Excludes corporate allocation
### Full Year 2023 Outlook

<table>
<thead>
<tr>
<th></th>
<th>February</th>
<th>May</th>
<th>August</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Organic Sales Growth</strong></td>
<td>5-6% (cc)</td>
<td>6-7% (cc)</td>
<td>7-7.5% (cc)</td>
</tr>
<tr>
<td><strong>aEBITDA</strong></td>
<td>$255-$265mm</td>
<td>$259-$267mm</td>
<td>$262-$270mm</td>
</tr>
<tr>
<td><strong>Depreciation</strong></td>
<td>~$85mm</td>
<td>~$85mm</td>
<td>~$85mm</td>
</tr>
<tr>
<td><strong>Interest Expense</strong></td>
<td>~$23mm</td>
<td>~$23mm</td>
<td>~$23mm</td>
</tr>
<tr>
<td><strong>Effective Tax Rate</strong></td>
<td>~20%</td>
<td>~20%</td>
<td>~20%</td>
</tr>
<tr>
<td><strong>aEPS</strong></td>
<td>$2.15-$2.30</td>
<td>$2.18-$2.32</td>
<td>$2.22-$2.36</td>
</tr>
</tbody>
</table>

**Comments**

- Increased full year growth and profit outlook
- Sales outlook including recent acquisitions:
  - ~$1.7b total Enovis sales
  - ~1% FY growth from acquisitions (~2% in the second half)
- Assumes latest FX rates hold
  - ~1-2% sales benefit in the second half

Improving sales, profit and earnings guidance based on strong Q2 performance